To the full analysis
American Healthcare REIT stock: growth
AHRAmerican Healthcare REIT reported $2.26B in revenue for fiscal 2025, up 9.1% on the prior year, up 13.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.7%
per year from 2016 to 2025, per share −4.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
10.3%
per year from 2016 to 2025, per share −3.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 13.8% | 9.7% |
| Revenue per share | −5.4% | −4.3% |
| Earnings | 100.3% | no data |
| Earnings per share | 66.6% | no data |
| Free cash flow | 12.8% | 10.3% |
| Free cash flow per share | −6.2% | −3.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $980.3M | −$146.03M | $68.37M |
| 2017 | $1.05B | $11.22M | $84.55M |
| 2018 | $1.13B | $13.3M | $39.91M |
| 2019 | $1.22B | −$4.97M | $24.62M |
| 2020 | $1.18B | $2.16M | $90.85M |
| 2021 | $1.26B | −$47.79M | −$61.78M |
| 2022 | $1.62B | −$81.3M | $76.25M |
| 2023 | $1.86B | −$71.47M | −$1.26M |
| 2024 | $2.07B | −$37.81M | $84.15M |
| 2025 | $2.26B | $69.81M | $165.88M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Feb 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.